Short answer
Sight Sciences, Inc. (SGHT) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $20M (up 12.5% year over year) with net income of −$13M.
Q1 2026 key financials · XBRL
- Revenue
- $20M
- +12.5% YoY
- Net income
- −$13M
- +8.3% YoY
- Operating margin
- -63.0%
- Gross margin
- 86.2%
- EPS (diluted)
- −$0.24
- +14.3% YoY
Source: XBRL data from the Sight Sciences, Inc. (SGHT) Q1 2026 10-Q on SEC EDGAR. USD.
Sight Sciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No Risk Factors section provided; filing excerpt contains only forward-looking statement disclosures
- Reimbursement risk: Interventional Glaucoma reimbursement protection and broad Interventional Dry Eye coverage remain uncertain
- Regulatory risk: extensive government regulation could affect product commercialization and compliance
- Operational risk: third-party manufacturing expansion could increase costs and disrupt operations
- Financial risk: secured credit facility compliance and favorable payment terms remain uncertain
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sight Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.